7 Prime Minister Mr John Patrick Amama Mbabazi acknowledging how this is what makes Dei Biopharma Ltd different from other foreign biotechnology companies. MP Patrick Isiagi comments, “This is a project that is going to attract a lot of jobs and bring in a lot of foreign currency exchanges to our country and balance up our trade with the world, but will also reduce our import of drugs and we shall be exporting drugs instead.” Indeed, not only is Dei BioPharma Ltd providing revolutionary healthcare products for its home region, but it also branching out globally. Having already filed a patent for its malaria cure in the USA, Dr Magoola shares how big pharma is very interested in further collaboration with Dei BioPharma Ltd, particularly with how anti-microbial drugs resistance is a real problem that is pushing the world to rapidly discover new drugs. Dr Magoola states, “Our competitors are not in Africa but the developed world. Even in the developed world, our competitors are happily collaborating with us! Because our technologies are not only changing Africa, but the globe!” It is already clear to see the dedication of Dei BioPharma Ltd – and Dei Group as a whole – towards the health and wellbeing of both the people of Africa and around the world. This extends further to its Corporate Social Responsibility (CSR), which remains focused on helping those who are in need and living in underprivileged communities, in the areas of health, education, drinking water, and sanitisation. Dei BioPharma Ltd utilises its own internal resources, such as research, marketing, financial, human resources, and products to maximise its ability to help, have an impact, and increase the reach of its CSR efforts. Also, within this commitment, the company’s EHS (Environmental, Health, and Safety) Policy means it maintains a safe, clean, and healthy working environment for its employees and served communities. By adhering to the highest standards in its plant design, equipment selection, maintenance, and operations, Dei BioPharma Ltd’s EHS Policy remains at its core. Also, it has established an ISO14001:2015 compliant Environmental Management System and ISO 45001:2018 compliant Occupational Health and Safety Management System at its facility, further underscoring its dedication. Dei BioPharma facilities have been built to meet the most stringent global Current Good Manufacturing Practices (cGMP) including US FDA and EU EMA and WHO standards among others. Ultimately, it is highly evident how Dei BioPharma Ltd has come to be recognised as Best Vaccine Manufacturing Pharma Company 2024 within the African Excellence Awards, with its outstanding vaccine offering, which is made possible through cutting-edge facilities and expert staff. It is an organisation that goes above and beyond, extending its work further to perform crucial, trailblazing medical research and manufacture life-saving medicines. The company has solidified its position on the global map as an industry leader, with the vital role it is playing within our healthcare industry today. Considering all this, we at MEA Markets magazine simply cannot wait to see what this best-in-class organisation does next. Company: Dei BioPharma Ltd Contact: Dr Matthias Magoola Email: [email protected] Website: www.deibiopharma.com Ι www.deigroupinternational.com
RkJQdWJsaXNoZXIy NTY1MjM3